31 results about "Antibody response" patented technology

The invention provides a pepsinogen II determination kit and a quantitative determination method, the kit comprises a reagent R1 and a reagent R2, the reagent R1 comprises a luminous donor molecule labeled pepsinogen II first antibody and a reaction buffer solution; and the R2 reagent comprises a light-emitting receptor molecule labeled pepsinogen II second antibody and a reaction buffer solution. A double-antibody sandwich structure marked by a luminescent donor and a luminescent receptor respectively is adopted, binding and luminescence can be completed in a liquid phase, solid phase coating and subsequent multi-step washing are not needed, real homogeneous detection and one-step incubation are achieved, the operation process is simplified, the detection time is shortened, and a full-automatic platform is adapted; and an improved buffer system can inhibit non-specific adsorption and reduce heterotropism interference such as RF / HAMA, so that the detection accuracy and repeatability are improved.

AAV vectors are ideally suited for long-term delivery of a combination of broadly neutralizing antibodies to achieve sterilizing immunity to HIV. Unfortunately, host immune responses to the delivered antibody have severely limited the efficacy. The TLR9 pathway has been identified in initiating adaptive immune responses against AAV and delivered bNAbs. To enhance this strategy, we validated Hydroxychloroquine, a known drug inhibitor of the TLR9 pathway, as a pretreatment to AAV delivery to avoid anti-drug antibody responses. TLR9 signaling inhibition was validated using a HEK-Blue hTLR9 reporter cell line and CpG stimulation. Hydroxychloroquine was also validated in a 3-macaque trial where AAV9-3BNC117 and AAV9-10-1074 were administered along with 3 doses of hydroxychloroquine once a week starting 1 week before AAV inoculation. Unlike historical controls, where 3BNC117 and 10-1074 expression is lost within the first 4-5 weeks, 2 macaques maintained 10-1074 expression and 1 macaque maintained 3BNC117 for the duration of the trial. Anti-3BNC117 antibodies were only observed in 2 of the 3 macaques and were significantly delayed. Anti-10-1074 antibody responses were a log lower than typically observed in historic controls. The use of hydroxychloroquine as a pretreatment for AAV inoculation is a promising strategy. The significant decrease in anti-10-1074 antibody levels and the successful delivery of 10-1074 in 2 macaques and 3BNC117 in 1 macaque was very encouraging. Extending the dosage of hydroxychloroquine beyond 3 doses may be sufficient to observe long-term bNAb expression in all animals and further decrease ADA responses. Together, these data suggest that the short-term treatment of hydroxychloroquine at the time of AAV inoculation has a meaningful impact on tolerance induction to our AAV-delivered bNAbs.

This invention relates to the field of reaction chamber technology, specifically an antigen-antibody reaction chamber, comprising a chamber body with three mounting openings on the outside for mounting windows one, two, and three, respectively. The cross-section of the chamber body is an outer shell, and the top of the outer shell has a top mechanism with rotating pins at both ends inserted into the two sides of the top of the outer shell. One side of the lower outer wall of the top of the outer shell is connected to an antigen chamber, and the other side is connected to an antibody chamber. The lower parts of the antigen chamber and antibody chamber are connected to the second air bladder of the reaction device via gas inlet tubes. The soft baffle in the inlet initially touches the inlet of the inlet tube, and then the inlet begins to break through the soft baffle, causing the reagent inside the antigen chamber to flow out along the long tube and then into the reaction device. The antigen reagent and the antibody reagent flowing into the reaction device at the same time specifically bind, thereby accelerating the specific binding rate of antigen and antibody inside the reaction device.

The application discloses a kind of natural product antiviral drug screening method based on hexagon protein and application, belong to active ingredient screening and antiviral drug development field.The method includes: preparation nitrogen-doped mesoporous carbon and silver nanosheet composite solution, drop coating on the surface of pretreated glassy carbon electrode, after drying by activation, hexagon protein incubation, blocking and enzyme label antibody reaction, construct electrochemical sensing electrode;With the electrode, the sample to be screened natural product is incubated, and the current response signal is detected;According to signal change combination inhibition rate formula evaluation antiviral activity.The application takes hexagon protein as recognition target, based on the principle of competitive immunoassay, realizes the specific, high sensitivity detection of antiviral active ingredient in natural product, with the advantages of fast operation, low cost, small sample consumption, high throughput, etc., provides effective technical support for the mining of antiviral active ingredient in natural product such as traditional Chinese medicine.

This invention provides a method for preparing a non-natural humanized chimeric anti-human CD45RA antigen receptor, which specifically binds to the human CD45RA antigen by expressing CAR protein on T cells. Based on a humanized 3A4 antibody, this invention constructs a lentiviral expression vector pLenti / Hu3A4-4-1BB-3ζ. Compared with murine CAR, the humanized CAR significantly reduces immunogenicity, noticeably decreases the production of anti-scFv antibodies, and avoids the HAMA reaction. Research results show that Hu3A4CAR-T cells can specifically bind to the CD45RA-highly expressing myeloid leukemia cell line KG1a. Hu3A4CAR-T cells can target and kill 3A4-positive cell lines and leukemia cells, alleviate the human anti-mouse antibody response, and significantly reduce the production of anti-scFv antibodies, thereby ensuring the CAR's killing activity.

This invention provides a recombinant Staphylococcus aureus enterotoxin B nanoparticle protein vaccine, mSEB-mi3, its preparation method, and its applications. This invention utilizes a SpyTag / SpyCather protein linker system to connect the recombinant protein to the nanoparticle protein, allowing mSEB to be displayed on the surface of self-contained nanoparticles, thus obtaining the recombinant Staphylococcus aureus enterotoxin B nanoparticle protein mSEB-mi3. Both mSEB-SpyTag and SpyCather-mi3 proteins in this invention are induced to be expressed in soluble form in Escherichia coli. The mSEB-SpyTag and SpyCather-mi3 of this invention can be covalently bound via isopeptide bonds to form the mSEB-mi3 nanoparticle protein vaccine. The binding conditions are simple, and when combined with the adjuvant MF59, it can induce rapid antibody production in mice, generating a high-level immune response and exerting a protective effect. Furthermore, its antibody response rate and protective efficiency are superior to those of the monomeric protein mSEB.

An objective of the present invention is to provide methods for promoting antigen uptake into cells by antigen-binding molecules, methods for increasing the number of times of antigen binding by one antigen-binding molecule, methods for promoting reduction of the antigen concentration in plasma by administering antigen-binding molecules, and methods for improving the plasma retention of an antigen-binding molecule, as well as antigen-binding molecules that allow enhanced antigen uptake into cells, antigen-binding molecules having an increased number of times of antigen binding, antigen-binding molecules that can promote reduction of the antigen concentration in plasma when administered, antigen-binding molecules with improved plasma retention, pharmaceutical compositions comprising the above antigen-binding molecules, and methods for producing them. The present inventors revealed that the above objective can be achieved by using antigen-binding molecules that show calcium-dependent antigen-antibody reaction.

The application relates to the technical field of biological detection, and discloses a labeling method for improving sensitivity and stability of a kit and application and the kit, which comprises the following steps: reacting Traut's reagent with an antibody to obtain a thiolated antibody by hydroxylamine deprotection; incubating the thiolated antibody with a blocking solution containing mPEG-NHS; reacting a heterotypic bifunctional crosslinking agent with alkaline phosphatase to obtain activated alkaline phosphatase after quenching; coupling: incubating the blocked thiolated antibody with the activated alkaline phosphatase in a coupling buffer to obtain an enzyme-labeled antibody. The application realizes directional labeling of alkaline phosphatase polymer on the antibody, improves the affinity of the antibody-alkaline phosphatase complex, has short process time, simple steps, small risk points in the process amplification process, can be controlled, and can reduce cost and increase efficiency. The scheme does not need to use dangerous reagents, the method has strong universality, wide application range, and improved sensitivity and stability performance of the corresponding product kit.

The invention provides a prevention and control method for cynomolgus monkeys based on SRV virus detection, and belongs to the technical field of cynomolgus monkey SRV virus detection, the cynomolgus monkeys after birth are subjected to intensive SRV antigen PCR and SRV antibody ELISA detection and are fed and managed in groups, negative animals after 9 months are subjected to annual quarantine, positive animals stop quarantine and are subjected to positive management by default, and the cynomolgus monkeys after birth are subjected to SRV antigen PCR detection and SRV antibody ELISA detection by default. The antibody positive and / or antigen positive belongs to the positive category. According to the method, SRV antigen PCR and SRV antibody ELISA detection are densely carried out on the cynomolgus monkeys after birth, grouping feeding management is carried out, early prevention and control can cut off a transmission chain, recessive infection can be effectively recognized, partially-infected monkeys are low in antibody reaction and even cannot be detected, but long-term detoxification can be achieved, recessive infection sources can be accurately removed by combining PCR and serological detection in the baby monkey period, and the method has the advantages of high specificity, high sensitivity, high sensitivity and the like. Although the detection cost is invested in the early stage, huge losses such as treatment, animal elimination and experiment repetition caused by disease outbreak in the future can be avoided.

To provide a clinically proven, safe, and clinically proven effective treatment for ulcerative colitis, particularly moderate to severe active ulcerative colitis. [Solution] To provide a method and composition for the clinically proven safe and effective treatment, as per the product label, of ulcerative colitis, particularly moderate to severe active ulcerative colitis, in patients who have had an insufficient response to or are intolerant of conventional or existing therapies involving intravenous and / or subcutaneous administration of anti-IL-12 / IL-23p40 antibodies.

A compound or a salt thereof comprising: (A) an affinity polypeptide including an affinity moiety having affinity for a heavy chain CH2-CH3 interdomain region of an antibody; (B) a first antibody reactive group; and (C) a second antibody reactive group. The affinity polypeptide includes first and second amino acid residues each having a side chain amino group, and the first antibody reactive group and the second antibody reactive group are linked to the affinity polypeptide via linkers that are introduced into the side chain amino groups of the first and second amino acid residues each having the side chain amino group, respectively.

The application discloses a blocking agent for milk allergen component-specific IgE antibody test strips and application, and belongs to the technical field of immune detection and analysis. The blocking agent uses soybean protein isolate and fish gelatin as the blocking agent in antigen-antibody reaction of immunoserological technology, so as to reduce false negative results caused by using conventional blocking agents, casein and bovine serum albumin, and thus makes the detection result more accurate.

This invention belongs to the field of reagent detection technology and discloses a diagnostic kit for P200 type pemphigus. The kit comprises human dermal extract protein strips, LM521 / LM421 / LM411 / LM111 recombinant protein strips, a positive control, a negative control, enzyme-labeled IgG antibody, enzyme-labeled IgA antibody, reaction buffer, washing buffer, and enzyme matrix solution. This invention simplifies the complex immunoblotting technique, using human dermal extract and various LMγ1 recombinant protein mixtures as antigens, and simultaneously analyzing IgG and IgA autoantibodies. It comprehensively solves the serological diagnostic problem of P200 type pemphigus in one step.

An immunoassay is described that enables a precise evaluation of immune responses in individuals exposed to Mpox or vaccinated with MVA, with high sensitivity and specificity. The serological assay targets three Orthopoxvirus antigens, MPXV-B6R, MPXV-A27L, and VACV-B5R, which are sufficient to quantify antibody responses to both MVA-vaccination (VACV-B5R) and, separately, infection (MPXV-B6R). The three antigen titres can be combined in a simple function [sum of ((MPXV-B6R) / VACV-B5R) and (MPXV-A27L)] to provide a numerical test score that can be compared with a reference (threshold) value to differentiate between post infection and post vaccination immune responses.

The invention relates to the technical field of biological medicine, in particular to fusion protein and application thereof in preparation of products for treating or preventing hepatitis B virus. PreS1 is used as a core antigen component and modified IgM is used as a basic skeleton to obtain a preS1-IgM monomer, then J chain connection is performed to obtain fusion protein, the fusion protein is used as an active component to construct the therapeutic vaccine, anti-preS1 antibody response can be effectively stimulated, and Th1 / Th2 immune response can be synergistically activated. Experiments show that serum HBsAg, HBV DNA and intrahepatic virus antigen levels of a chronic HBV infection model can be remarkably reduced by using the vaccine alone, and serological conversion of part of animals is realized; when the compound is combined with entecavir, the compound shows an excellent synergistic effect. According to the vaccine, the treatment effect is remarkably improved, meanwhile, remarkable liver injury is not caused, and an innovative immunotherapy with prevention and treatment functions is provided for chronic hepatitis B treatment.

The present invention relates to an intestinal microorganism-based composition for enhancing the efficacy of vaccinations, in particular, the persistence of antibody reactions and booster effects. The present inventors have found that specific intestinal microorganisms are significantly abundant in individuals having a long antibody half-life following vaccination with an mRNA vaccine or an adenovirus vector vaccine, or exhibiting a high immune response upon booster vaccination. Specifically, it was found that a specific microbial community including Faecalibacterium prausnitzii is associated with antibody persistence and booster response enhancement following mRNA vaccination, and Escherichia coli is associated with antibody persistence following adenovirus vector vaccination.

The invention provides a mycoplasma bovis specific antigen epitope peptide and application thereof in antibody detection, and the amino acid sequence of the antigen epitope peptide is SEQ ID NO: 1. Bioinformatics prediction and serological verification are carried out on mycoplasma bovis immunogenic protein, the antigen epitope peptide highly associated with antibody reaction specificity is obtained through screening, a high-specificity mycoplasma bovis antibody detection method can be established by using the epitope peptide, the detection specificity is 100%, the sensitivity is 98.8%, and the detection time is short. And an effective tool is provided for serological diagnosis of mycoplasma bovis infection.

The present application relates to the technical field of biological medicine, and particularly relates to a fusion protein and application thereof in preparation of a product for treating or preventing hepatitis B virus. The present application takes preS1 as a core antigen component and takes an improved IgM as a basic skeleton to obtain a preS1-IgM monomer, and then connects the preS1-IgM monomer through a J chain to obtain a fusion protein. The fusion protein is taken as an active component to construct a therapeutic vaccine, which can effectively stimulate an anti-preS1 antibody response and synergistically activate a Th1 / Th2 immune response. Experiments show that the vaccine alone can significantly reduce the serum HBsAg, HBV DNA and intrahepatic virus antigen levels of a chronic HBV infection model, and realize seroconversion of part of the animals. When the vaccine is used in combination with entecavir, a remarkable synergistic effect is exhibited. The vaccine significantly improves the therapeutic effect without causing significant liver damage, and provides an innovative immunotherapy with both prevention and treatment functions for chronic hepatitis B treatment.

A method for quantifying the amount of neurofilament light chains (NFLs) in a blood sample, comprising the steps of adding a composition containing polyanionic molecules and reacting it with at least one antibody conjugated to a detection system that specifically binds to one epitope of an NFL, and its use for diagnostic purposes and a corresponding diagnostic kit.

The invention relates to the technical field of vaccine adjuvants, in particular to an oil-in-water type nano emulsion adjuvant. The adjuvant comprises the following components in percentage by weight: 4.65%-8.51% of squalene or an oil phase matrix containing squalene, 0.45%-2.63% of a zwitterionic surfactant, 0.90%-5.19% of a polyoxyethylene nonionic surfactant and 0.22%-0.88% of a polyethylene glycol-fatty acid ester nonionic surfactant, and water is used as a continuous phase of the adjuvant. The vaccine can induce potent humoral immunity and cellular immunity responses, can induce antibody responses at mucous membrane parts such as intestinal tracts and vaginas after injection inoculation, and can induce an organism to generate comprehensive and effective immune defense aiming at pathogens.

The present invention provides novel variants of varicella-zoster virus gE protein, mRNA vaccines encoding the gE variants or gE variant fusion proteins. The mRNA vaccine based on the gE variant or the gE variant fusion protein can induce high-level IgG antibody reaction, T cell immune response and T cell immune memory.

This invention provides a nanoparticle protein, MntC-rePO@LS, its preparation method, and its applications. This protein is formed by the covalent binding of MntC@LS and recombinant V antigen-outer membrane protein OprI (rePO) via heteropeptide bonds, creating a dual-nanoparticle vaccine molecule. The recombinant protein SpyCatcher-MntC@LS of this invention can be induced to express in soluble form in *E. coli* and can bind efficiently to the recombinant protein rePO-SpyTag under mild conditions. The nanoparticle protein of this invention can induce a high level of immune response in animals, exerting an immunoprotective effect. Experiments show that its rate of antibody response induction and protective efficiency are significantly superior to those of monomeric MntC, monomeric rePO, and their physical mixtures, and it can be used for the prevention and treatment of *Pseudomonas aeruginosa* and / or *Staphylococcus aureus* infections.

A method of use of a synthetic SCGB, and compositions thereof, to prevent the development or reduce the development of antibodies against a foreign antigen or set of antigens in the subject that receives the antigen(s) is provided. A synthetic SCGB being recombinant human CC10 protein is provided. The foreign antigen(s) is / are a cell, tissue or organ from a donor subject is administered, introduced, or transplanted into a recipient subject, a lung transplant, transplanted kidney, heart, liver, hematopoietic cell, or any other tissue or organ, antigen(s) is / are from human or non-human origin, purified therapeutic proteins or other drugs, food or drink, self-antigen or an allergen.

A cyclic draining and replenishing (CDR) antibody reaction apparatus according to the present invention comprises: a chamber part inside which an antibody solution is accommodated, and in which a blotting membrane that reacts with the antibody solution is arranged; and a spreader arranged on the blotting membrane in the chamber part, wherein the position of the spreader moves along the top of the blotting membrane.

The invention provides a nanofiber adjuvant and application thereof, and belongs to the technical field of biological medicines and vaccines. The nano fibrous adjuvant disclosed by the invention is formed by connecting muramyl dipeptide and flexible polypeptide, and the flexible polypeptide is glycine-glycine-phenylalanine-phenylalanine-naphthalene ring. The C end of the muramyl dipeptide molecule and the N end of the GGFF-Nap polypeptide are subjected to dehydration condensation to form a peptide bond, the bis-glycine is used as a flexible linker, and the bis-phenylalanine-naphthalene ring provides aromatic nucleus interaction. Under the assistance of GGFF-Nap, the muramyl dipeptide can be self-assembled into the nanofiber adjuvant with a nanofiber structure. The nanofiber adjuvant can precisely regulate and control the fate of B cells through multivalent co-display antigens, prepare long-acting antibody response vaccines, prolong the antibody response period and provide service for improving the durability of the vaccines.

Disclosed herein are adjuvanted protein vaccines comprising: a non-phospholipid liposome and one or more proteins, wherein the protein is encapsulated within the non-phospholipid liposome, and wherein the protein is selected from:(i) a modified full-length spike protein that generates IgG antibody responses for 120 days after two injections of the adjuvanted protein vaccine, by subcutaneous or intramuscular routes;(ii) a modified spike protein sequence of a coronavirus;(iii) a protein sequence from a coronavirus; and(iv) a protein from an infectious agent that generates IgG antibody responses to proteins after one or two subcutaneous or intramuscular injections.Also disclose herein are modified spike protein sequence containing a modified full-length SARS-COV-2 spike protein sequence. Methods of use of the vaccines and sequences are also disclosed herein.

The invention relates to the technical field of biological detection, and discloses a target pathogenic bacterium immune antibody detection method based on DNA detection. The method comprises the following steps: acquiring target pathogenic bacterium DNA sequence data and immune antibody protein expression quantity data of a biological sample to be detected; mutation site scanning is carried out on the DNA sequence data of the target pathogenic bacteria, the boundary of a high-frequency mutation region is recognized, and the sequence mutation degree is calculated; periodically fluctuating characteristics of antibody expression quantity data are synchronously extracted, and antibody response intensity indexes are generated; determining an immune escape risk coefficient by analyzing the historical correlation and the change trend collaboration degree of the two; constructing an antibody inhibition trend factor by combining the recent decline slope of the expression quantity of the antibody and the rising rate of the DNA copy number of the target pathogenic bacteria; fusing the coefficient and the factor to generate an adaptive evolution index of the target pathogenic bacteria; dynamically adjusting an antibody affinity detection threshold according to the index change gradient and a preset sensitivity threshold; and screening data based on the adjusted threshold, and outputting an effective neutralizing antibody set.

The application relates to a multi-mode portable carcinoembryonic antigen detection sensor based on manganese dioxide nanoflower, the application uses a MnO2NFs-labeled detection antibody as a detection probe, and carcinoembryonic antigen and the probe are sequentially added to a paper base which is modified with a capture antibody; due to a specific antigen-antibody reaction, the three form a sandwich complex. At this time, the concentration of the carcinoembryonic antigen is positively correlated with the amount of the MnO2NFs finally fixed to the paper base. The multi-mode portable carcinoembryonic antigen detection sensor can realize detection of carcinoembryonic antigen through three visual signals of color, temperature and distance. The three signals are complementary to each other and are mutually verified, thus providing a new method and thought for development of the sensor. The construction method is simple, the sensitivity is high, the specificity is good, the detection limit is low, and the linear range is wide, and the carcinoembryonic antigen CEA can be sensitively detected, the linear range is 2.5-100 ng / mL, and the detection limits of the three signals are 1.4 ng / mL, 1.5 ng / mL and 2.5 ng / mL respectively.

The application provides a drug-loaded nanoparticle Cor@PDA-PEG@CD11b and a preparation method and application thereof, the preparation method comprises the following steps: S1, mixing cordycepin solution and PDA aqueous solution, so that the cordycepin and the PDA form a complex Cor@PDA through π-π stacking effect; S2, the obtained complex Cor@PDA is modified by PEG to prepare a complex Cor@PDA@PEG; S3, the obtained Cor@PDA@PEG is dispersed in a buffer solution, and an anti-CD11b antibody is added; after reacting for 24h, centrifugation, washing, collecting the precipitate, and drying, the Cor@PDA-PEG@CD11b is obtained. The drug-loaded nanoparticle Cor@PDA-PEG@CD11b prepared by the application provides a new idea and direction for the treatment of sepsis-related lung injury; through the characteristics of the PDA nanoparticles, the cordycepin is released in a controlled manner, and the problem that the cordycepin is rapidly oxidized and inactivated after entering the body is avoided, the bioavailability is improved, the specific antibodies on the surface of immune cells and the physiological characteristics are utilized, the immune cells are quickly and chemotactically recruited to the inflammatory injury site in the early stage of acute inflammation, the drug is quickly and accurately targeted, and the sepsis lung injury is reduced.

Provided is a method for detecting a drug antibody in a specimen. In the present disclosure, the drug antibody is detected by flow cytometry for the first time. During the detection, self cells of a patient are used as indicator cells. Moreover, nine systems are set up, including: a blank system, a negative control system, a positive control system, a self—control system, a drug—sensitized self—cell control system, a drug—antibody reaction detection system, an enzyme—sensitized self—control system, an enzyme—reaction drug detection system, and an enzyme—reaction drug control system. The method avoids interference from autoantibodies and irregular antibodies of red blood cells, and also avoids a false positive result of detection caused by combination of enzymes or drugs with self red blood cells. The method for detecting a drug antibody can simultaneously detect an affinity of the drug antibody to red blood cells and identify a type of the drug antibody.